×
Business / Stock Market

Biogen Announces Positive CHMP Opinion For VUMERITY - Quick Facts

Published Sep 17 2021 at 1:51 PM GMT
Business Insider

Business Insider @businessinsider.com

Continue reading at businessinsider.com
Key
Points
  • (BIIB) announced the Committee for Medicinal Products for Human Use has recommended granting marketing authorization for VUMERITY in the European Union.
  • VUMERITY is a next-generation oral fumarate for the treatment of adults with relapsing-remitting multiple sclerosis.
  • The company said the positive CHMP opinion was based.
Credit
Tags
Continue reading at businessinsider.com
Trending

Stats

  • Published Sep 17, 2021 1:51 PM GMT